key: cord-0989429-911szzte
authors: Dai, Xiaofeng; Ostrikov, Kostya
title: ROS-Driven selection pressure on COVID-19 patients with cardiovascular comorbidities
date: 2021-04-27
journal: Innovation (N Y)
DOI: 10.1016/j.xinn.2021.100107
sha: 41abe32d1328e4c7a0b9d9b7ec5e6559d5fed4ff
doc_id: 989429
cord_uid: 911szzte

Coronavirus disease 2019 (COVID-19) has imposed a global health threat which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently available data point out that ACE2, the receptor of SARS-CoV-2 in host cells, does not predispose the risk or severity of COVID-19, but rather elevated levels of reactive oxygen species (ROS) impose abnormal selection pressure on patients having cardiovascular comorbidities. As clinical and preventative practice, ROS scavengers are thus recommended for effective therapeutic control of COVID-19 and cardiovascular diseases.

Coronavirus disease 2019 (COVID-19), a novel pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has emerged in China, and soon been declared as a global pandemic. Currently available data suggest that patients with cardiovascular diseases are more likely to develop severe COVID-19 as, for example, 71% severe COVID-19 patients have been reported hypertensive. 1 It was proposed that the association between COVID-19 severity and cardiovascular comorbidities could be attributed to increased ACE2 (the receptor mediating SARS-CoV-2 entry 2 ) expression in cells of COVID-19 patients having cardiovascular diseases. 3 However, ACE2 expression plays a beneficial role in maintaining blood pressure and fluid and electrolyte homeostasis, 3 rendering its merely detrimental role in COVID-19 patients coupled with cardiovascular diseases arguable.

ACE promotes cardiovascular diseases by converting angiotensin I (ANGI) to ANGII, and acts as a common target for hypertension control. 3 ACE2 counteracts the J o u r n a l P r e -p r o o f effect of ACE via competing with ACE in converting ANGI to ANG-(1-9), 3 and confers many beneficial effects to human health such as protection against LPS-induced acute lung injury in vivo, attenuation of inflammatory response and oxidative stress in hyperoxic lung injury, and attenuation of cardiovascular dysfunction in adult male offspring of hypertensive pregnant rat. Hypertensive patients have, in general, over-activated ACE 3 , and thus low ACE2 expression. Therefore, though patients carrying cardiovascular diseases are more likely to develop severe COVID-19 infection, 1 this does not mean that individuals suffering from hypertension are more susceptible to SARS-CoV-2 infection than the others. On the contrary, hypertension may have reduced risk of SARS-CoV-2 infection due to decreased ACE2 expression. Therefore, ACE2 plays dual roles in COVID-19 patients carrying cardiovascular diseases, i.e., mediating virus entry and alleviating cytokine storm, which complicate the development of preventative and therapeutic strategies against SARS-CoV-2 infected cardiovascular patients targeting ACE2. Yet, the high binding affinity of ACE2 to SARS-CoV-2 (~15 nM, which is around 10 to 20 times higher than that to SARS-CoV) 2 may neutralize, at least partially, the risk of SARS-CoV-2 infection as predisposed by the differential ACE2 expression among individuals, and thus do not alter the risk or severity of hypertensive COVID-19 patients if treated with ACE inhibitors for hypertension control.

On the other hand, the higher occurrence of severe COVID-19 cases in elder males carrying comorbidities ( Figure 1A ) as reported by the many studies on COVID-19 manifestations 1 could be explained by the higher chance of developing cardiovascular and cerebrovascular diseases with age especially when exacerbated by hypertension in general; moreover, the chance is even higher among elder males. Therefore, patients suffering from high cardiovascular pressure have less chance to survive, and this may not be determined by ACE2 expression.

Among the many factors contributing to cytokine storm, the lethal cause of SARS-CoV-2 mortality, reactive oxygen species (ROS) are essential; excess ROS production is intimately related with acute lung injury. ROS, produced in all layers of the vascular wall by endothelial, smooth muscle and adventitial cells, have long been known as a cause or consequence of hypertension. The fundamental roles of concomitant ROS increase and reduced antioxidant capacity in the development of hypertension have been recognized both preclinically and clinically. Through mechanisms associated with quenching the vasodilator NO by O 2 -, generating vasoconstrictor lipid peroxidation products, depleting tetrahydrobiopterin, activating proinflammatory transcription factors, stimulating growth factor production, and inducing fibrosis, ROS trigger calcium influx, activate growth and inflammatory signaling, and increase extracellular matrix deposition, which collectively cause elevated blood pressure and constitute the 'vascular phenotype' in hypertension. On the other hand, increased ROS is accompanied with virus infection. Therefore, the aggregated disease severity of cardiovascular patients after SARS-CoV-2 infection may be driven by the elevated ROS level associated with virus infection in addition to J o u r n a l P r e -p r o o f the already high intrinsic redox level among cardiovascular patients. Miripour et al. established a real-time in vivo diagnostic platform for ROS detection, using which they reported a positive correlation between COVID-19 severity and ROS level. 4 Reduced frequency of fever, diarrhea, leukopenia and thrombocytopenia (common symptoms in response to virus infection) caused by SARS-CoV-2 as compared with SARS-CoV (Figure 1B) 1,5 may reflect a reduced level of ROS generation and cytokine secretion as a result of a weaker immune response against viral invasion. ROS may function as an alarm signal on pathogen invasion through manifesting clinically evident symptoms while stimulating the immune system to fight against it. Recessed effect on generating alarm signals such as ROS is evolutionarily advantageous for virus propagation and transmission. Indeed, less apparent infection symptoms complicate the diagnostic process and are associated with lower case-fatality rate, whereas delayed therapeutic intervention and prolonged life span of infected individuals effectively give more time for viruses to propagate in the current host and transmit to other hosts.

To this end, we argue that SARS-CoV-2 is an advanced next-generation coronavirus with lower lethality to hosts yet higher ability to reproduce and survive than SARS-CoV. The trigger of cytokine storm in SARS-CoV-2 infected individuals that ultimately leads to COVID-19 mortality could be perceived as a ROS-driven selection pressure for hosts. In diseases caused by viruses with high transmission capacity yet low perturbation on host redox homeostasis (such as SARS-CoV-2), intrinsic ROS level in host cells may determine the case-fatality rate. Furthermore, the evolutionary advantage of SARS-CoV-2 over SARS-CoV may prime its mutation towards symbiosis with humans.

The fundamental role of ROS in driving the SARS-CoV-2 virulence may justify the use of ROS scavengers such as vitamin C and N-acetylcysteine in ameliorating SARS-CoV-2 effects, especially among patients carrying cardiovascular disorders. Though these recommendations are subjected to rigorous experimental and clinical investigations, daily intake of food enriched with vitamin C might be a good way for health maintenance especially for individuals suffering from hypertension. COVID-19 patients having dyspnea may be placed under hyperoxic conditions using ventilators. The benefits may be subjected to the duration and flow of oxygen that may need to be carefully controlled to avoid unexpected conversion of oxygen to excess ROS.

It is possible that conclusions drawn from comparing SARS-CoV-2 and SARS-CoV is biased by the significantly different diagnostic techniques and treatment measures adopted in managing these two pandemics given the 17-year time distance. Yet, we only compared symptoms of SARS-CoV-2 and SARS-CoV patients that involves diagnostic approaches only. Techniques used for SARS-CoV-2 diagnosis should be more sensitive than those applied 17 years ago, and symptoms should be J o u r n a l P r e -p r o o f more evident than before if the same disease was diagnosed nowadays. However, recessed symptoms were observed for SARS-CoV-2 infection than those for SARS-CoV, suggestive of the soundness of the associated conclusions here.

The severity of COVID-19 patients may be exacerbated by cardiovascular diseases especially hypertension. High intrinsic ROS levels in patients with pre-existing cardiovascular diseases may constitute their survival disadvantage under the selection pressure imposed by virus infection and boost the case-fatality rate in patients. This may become particularly important when the virus is featured by low virulence and high transmission capacity such as SARS-CoV-2. Food and drinks enriched with ROS scavengers may, therefore, be recommended to assist in COVID-19 severity control especially among cardiovascular patients. 

The authors declare no competing interests.

XFD conceptualized the idea, drafted the manuscript and prepared the figure. KO contributed in manuscript finalization.

Xiaofeng Dai: xiaofeng.dai@jiangnan.edu.cn 

Clinical Characteristics of Coronavirus Disease 2019 in China

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

ABO blood group predisposes to COVID-19 severity and cardiovascular diseases

Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic